Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

S

Sherman KE, Andersen JW, Butt AA, et al. "Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)." J. Acquir. Immune Defic. Syndr.. 2010;55(5):597-605.
Sherman KE, Rouster SD, Stanford S, et al. "Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens." J. Infect. Dis.. 2010;201(5):712-9.
Sherman KE, Kang M, Sterling R, et al. "Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection." World J Hepatol. 2017;9(4):217-223.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Shiboski CH, Lee A, Chen H, et al. "Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy." AIDS. 2016;30(10):1573-82.
Shiboski CH, Chen H, Secours R, et al. "High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group." PLoS ONE. 2015;10(7):e0131001.
Shikuma CM, Ribaudo HJ, Zheng Y, et al. "Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals." AIDS Res. Hum. Retroviruses. 2011;27(5):461-8.
Shikuma CM, Yang Y, Glesby MJ, et al. "Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)." J. Acquir. Immune Defic. Syndr.. 2007;44(5):540-50.
Shikuma CM, Gangcuangco LMar A, Killebrew DA, et al. "The role of HIV and monocytes/macrophages in adipose tissue biology." J. Acquir. Immune Defic. Syndr.. 2014;65(2):151-9.
Shire NJ, Rao MB, Succop P, et al. "Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection." Clin. Gastroenterol. Hepatol.. 2009;7(4):471-80, 480.e1-2.
Shivakoti R, Yang W-T, Berendes S, et al. "Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings." J. Infect. Dis.. 2016;213(7):1074-8.
Shivakoti R, Yang W-T, Gupte N, et al. "Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation." Clin. Infect. Dis.. 2015;61(1):102-10.
Shivakoti R, Christian P, Yang W-T, et al. "Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults." Clin Nutr. 2016;35(1):183-9.
Shivakoti R, Gupte N, Yang W-T, et al. "Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy." Nutrients. 2014;6(11):5061-78.
Shulman NS, Kassaye SG, Winters MA, Johnston E, Katzenstein DA. "More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175." J. Infect. Dis.. 2007;196(2):328-9; author reply 329-30.
M Siddique A, Hartman KE, Dragileva E, et al. "Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy." J. Infect. Dis.. 2006;194(5):661-5.
Sieg SF, Bazdar DA, Lederman MM. "S-phase entry leads to cell death in circulating T cells from HIV-infected persons." J. Leukoc. Biol.. 2008;83(6):1382-7.
Simoni JM, Huh D, Wilson IB, et al. "Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study." J. Acquir. Immune Defic. Syndr.. 2012;60(5):466-72.
Simpson DM, Kitch D, Evans SR, et al. "HIV neuropathy natural history cohort study: assessment measures and risk factors." Neurology. 2006;66(11):1679-87.
Simpson KN, Dietz B, Baran RW, et al. "Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data." Cost Eff Resour Alloc. 2011;9:5.
Singini I, Campbell TB, Smeaton LM, et al. "Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy." HIV Clin Trials. 2016:1-8.
Sinxadi PZuleika, McIlleron HMargaret, Dave JAlex, et al. "Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations." Medicine (Baltimore). 2016;95(2):e2385.
Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM. "Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170." J. Acquir. Immune Defic. Syndr.. 2008;49(4):377-83.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.
Skinner-Adams TS, Butterworth AS, Porter KA, et al. "The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment." PLoS ONE. 2012;7(4):e34399.
Skowron G, Spritzler JG, Weidler J, et al. "Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects." J. Acquir. Immune Defic. Syndr.. 2009;50(3):250-8.
Smith DM, Mathews WChristophe. "Physicians' attitudes toward homosexuality and HIV: survey of a California Medical Society- revisited (PATHH-II)." J Homosex. 2007;52(3-4):1-9.
Smith KY, Tierney C, Mollan K, et al. "Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine." Clin. Infect. Dis.. 2014;58(4):555-63.
Smith DM, Drumright LN, Frost SDW, et al. "Characteristics of recently HIV-infected men who use the Internet to find male sex partners and sexual practices with those partners." J. Acquir. Immune Defic. Syndr.. 2006;43(5):582-7.
Smith DM, Strain MC, Frost SDW, et al. "Lack of neutralizing antibody response to HIV-1 predisposes to superinfection." Virology. 2006;355(1):1-5.

Pages